These data suggest that nearly all of the available approaches to immunotherapy, including activation of the STING pathway leading to interferon production, are capable of affecting NBL tumor growth, and therefore have the potential to be useful agents when employed in combination with locoregional therapies to counteract the effects of the locoregional therapy on systemic immune activation in NBL. This evidence concerns the gene STING1 and neoplasm.